Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 105 publications
Correction: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.
Journal: Journal of hematology & oncology
Published: August 11, 2026
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.
Journal: Investigational new drugs
Published: April 06, 2026
Quantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in the first-in-human LP-184 trial.
Journal: Cancer chemotherapy and pharmacology
Published: March 06, 2026
Multi-Omic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 02, 2025
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.
Journal: Journal for immunotherapy of cancer
Published: November 23, 2025
A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma.
Journal: Liver cancer
Published: October 07, 2025
Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors.
Journal: JAMA network open
Published: September 12, 2025
First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.
Journal: Journal of hematology & oncology
Published: July 19, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 27, 2025
A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma.
Journal: Cancers
Published: September 27, 2024
Aurkin-A, a TPX2-Aurora A small molecule inhibitor disrupts Alisertib-induced polyploidy in aggressive diffuse large B cell lymphoma.
Journal: Neoplasia (New York, N.Y.)
Published: March 22, 2024
Gene Expression Patterns Associated with Survival in Glioblastoma.
Journal: International journal of molecular sciences
Published: February 14, 2024
Last Updated: 09/26/2026